Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to share news the company will be looking at their drug Ifenprodil in a new clinical research program for Pancreatic Cancer.
Moreau telling Proactive Ifenprodil demonstrated a significant anti-tumour effect in an animal model which was reported in a paper published in the Dove Press Journal, Clinical Pharmacology: Advances and Applications. That report reported that Ifenprodil significantly and rapidly reduced the average solid tumour size by approximately 50%.